Ichnos Sciences Inc., a US-based clinical-stage global biotechnology company developing innovative multi-specific antibodies for oncology, announced on Monday that it has chosen ISB 2001, its first TREAT1 trispecific antibody, which engages BCMA x CD38 x CD3, as its next candidate to transfer into clinical development.
The firm has commenced IND-enabling studies for relapsed/refractory multiple myeloma and intends to advance ISB 2001 to a first-in-human study once approval from the health authorities is received in 2023.
The product is the first T cell-engaging antibody that is aimed at BCMA and CD38 on multiple myeloma cells. It is a trispecific antibody based on BEAT 2.0 technology.
China's BeiGene Opens Regional Office in Basel, Switzerland
Vraniak Named Chief Financial Officer at Inversago Pharma
New data from Sanofi's oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting
First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors
AbbVie and Cugene to collaborate on autoimmune diseases
Paige AI Solution for Prostate Cancer Biomarker Detection Receives CE-IVD and UKCA Marks